SN-28049

CN(C)CCNC(=O)C1=CN(C)C(=O)C2=C1N=C3C(C)=CC=CC3=C2

InChIKey=CSMRPIFORJZYCJ-UHFFFAOYSA-N

InChI=1S/C19H22N4O2/c1-12-6-5-7-13-10-14-17(21-16(12)13)15(11-23(4)19(14)25)18(24)20-8-9-22(2)3/h5-7,10-11H,8-9H2,1-4H3,(H,20,24)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

PubMed

Title	Date	PubMed
Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049).	2008-11-15	18926778
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.	2008-10	18175117

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:23:10 GMT 2025` Edited by `admin` on `Mon Mar 31 21:23:10 GMT 2025`
Record UNII	XNV0707AMP
Record Status	`Validated (UNII)`
Record Version

Name

Type

Language

BENZO(B)(1,6)NAPHTHYRIDINE-4-CARBOXAMIDE, N-(2-(DIMETHYLAMINO)ETHYL)-1,2-DIHYDRO-2,6-DIMETHYL-1-OXO-

Preferred Name

English

SN-28049

Common Name

English

Code System Code Type Description

FDA UNII

XNV0707AMP

Created by admin on Mon Mar 31 21:23:10 GMT 2025 , Edited by admin on Mon Mar 31 21:23:10 GMT 2025

PRIMARY

PUBCHEM

9862688

Created by admin on Mon Mar 31 21:23:10 GMT 2025 , Edited by admin on Mon Mar 31 21:23:10 GMT 2025

PRIMARY

EPA CompTox

DTXSID20197744

Created by admin on Mon Mar 31 21:23:10 GMT 2025 , Edited by admin on Mon Mar 31 21:23:10 GMT 2025

PRIMARY

CAS

492472-30-7

Created by admin on Mon Mar 31 21:23:10 GMT 2025 , Edited by admin on Mon Mar 31 21:23:10 GMT 2025

PRIMARY

Related Record Type Details


					XNV0707AMP

SN-28049

ACTIVE MOIETY